Want to see OCS full AI Analyst Report?

Oculis Holding (OCS) Price & Analysis

216 Followers

OCS Stock Chart & Stats

$11.13

-$0.13(-1.17%)

At close: Jul 27 4:00 PM EDT

$11.13

-$0.13(-1.17%)

Day’s Range― - ―

52-Week Range$10.52 - $34.48

Previous CloseN/A

Volume218.36K

Average Volume (3M)428.82K

Market Cap

$729.48M

Enterprise Value$569.93

Total Cash (Recent Filing)$221.37M

Total Debt (Recent Filing)$2.24M

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Nov 05, 2026

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.73

Shares Outstanding57,169,476

10 Day Avg. Volume294,756

30 Day Avg. Volume428,824

Financial Highlights & Ratios

PEG Ratio0.60

Price to Book (P/B)4.22

Price to Sales (P/S)0.00

P/FCF Ratio-13.27

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$37.60

Price Target Upside237.83% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.75

Revenue Forecast (FY)$754.37K

Bulls Say, Bears Say

Bulls Say

Strong Liquidity / Cash RunwayA large cash and short-term asset base (CHF ~228m) and management disclosure of runway into H2 2029 provide multi-year funding for clinical programs. This materially reduces near-term refinancing pressure and supports completion of registrational trials without immediate dilution.

Low Leverage / Robust Balance SheetExtremely low debt and a sizable equity base give Oculis financial flexibility to fund R&D, absorb trial setbacks and pursue M&A or licensing. Low interest burden preserves cash for operations and reduces bankruptcy/default risk versus highly levered peers.

Strategic Asset Control & Regulatory ProgressAcquiring full rights to Privosegtor removes legacy license encumbrances and concentrates upside from approvals; combined with FDA pre-IND feedback, Breakthrough/PRIME designations and an SPA, this structurally strengthens commercial potential and strategic control over a lead asset.

Bears Say

Sustained Cash BurnPersistent negative operating and free cash flow at ~-$62m TTM indicates ongoing high cash consumption to fund trials and operations. Absent a major revenue or cost shift, continued burn necessitates future financing, which can dilute shareholders and constrain strategic optionality.

Minimal Commercial Revenue; Large LossesWith essentially no recurring commercial revenue and a roughly $95M TTM net loss, Oculis lacks operating leverage. The business remains dependent on successful clinical outcomes to generate material sales, making long-term profitability contingent on high-risk development milestones.

Ongoing Dilution / Capital Raise FlexibilityBoard authorization of expanded share capital, issuance capacity and active use of equity for funding signals structural reliance on equity markets. While it preserves funding flexibility, it creates persistent dilution risk and an overhang that can depress per-share economics if further issuances are required.

Oculis Holding News

Oculis price target lowered to $32 from $35 at BofA

BofA analyst Jason Gerberry lowered the firm’s price target on Oculis (OCS) to $32 from $35 and keeps...

2d ago

OCS

Oculis to acquire development, commercial rights to Privosegtor from Accure

Oculis (OCS) and Accure Therapeutics announced that Oculis and Accure have entered into an asset purchase agreement whereby,...

2d ago

OCS

Oculis reports Q2 EPS (16c), consensus (38c)

Riad Sherif, Chief Executive Officer of Oculis (OCS), stated, “We continue to advance and expand the Privosegtor neuroprotection...

6d ago

OCS

Oculis gets FDA pre-IND feedback regarding Privosegtor clinical development plan

Oculis (OCS) announced FDA pre-IND feedback regarding Privosegtor’s clinical development plan in acute multiple sclerosis relapses. Privosegtor is...

9d ago

OCS

Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics

The latest announcement is out from Oculis Holding ( ($OCS) ). On August 10, 2026, Oculis Holding AG...

2d ago

OCS

Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing

The latest update is out from Oculis Holding ( ($OCS) ). On August 6, 2026, Oculis Holding AG...

5d ago

OCS

Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating

Oculis Holding, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from...

7d ago

OCS

Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch

Oculis Holding Ag ($OCS) announced an update on their ongoing clinical study. The study “A Randomized, Double-masked, Placebo-controlled...

1M ago

OCS

Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway

The latest announcement is out from Oculis Holding ( ($OCS) ). On June 25, 2026, Oculis Holding AG...

2M ago

OCS

Oculis price target lowered to $23 from $42 at JPMorgan

JPMorgan lowered the firm’s price target on Oculis (OCS) to $23 from $42 and keeps an Overweight rating...

2M ago

OCS

Oculis price target lowered to $38 from $49 at Baird

Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating...

2M ago

OCS

Oculis price target lowered to $38 from $49 at Baird

Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating...

2M ago

OCS

Video: Nvidia rallies after taking wraps off new PC processor

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

2M ago

AMD

OCS

Oculis price target lowered to $35 from $44 at BofA

BofA lowered the firm’s price target on Oculis (OCS) to $35 from $44 and keeps a Buy rating...

2M ago

OCS

OCS FAQ

What was Oculis Holding Ag’s price range in the past 12 months?

Oculis Holding Ag lowest stock price was $10.52 and its highest was $34.48 in the past 12 months.

What is Oculis Holding Ag’s market cap?

Oculis Holding Ag’s market cap is $729.48M.

When is Oculis Holding Ag’s upcoming earnings report date?

Oculis Holding Ag’s upcoming earnings report date is Nov 05, 2026 which is in 85 days.

How were Oculis Holding Ag’s earnings last quarter?

Oculis Holding Ag released its earnings results on Aug 06, 2026. The company reported -$0.198 earnings per share for the quarter, beating the consensus estimate of -$0.48 by $0.282.

Is Oculis Holding Ag overvalued?

According to Wall Street analysts Oculis Holding Ag’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oculis Holding Ag pay dividends?

Oculis Holding Ag does not currently pay dividends.

What is Oculis Holding Ag’s EPS estimate?

Oculis Holding Ag’s EPS estimate is -0.5.

How many shares outstanding does Oculis Holding Ag have?

Oculis Holding Ag has 57,169,476 shares outstanding.

What happened to Oculis Holding Ag’s price movement after its last earnings report?

Oculis Holding Ag reported an EPS of -$0.198 in its last earnings report, beating expectations of -$0.48. Following the earnings report the stock price went up 2.423%.

Which hedge fund is a major shareholder of Oculis Holding Ag?

Currently, no hedge funds are holding shares in OCS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oculis Holding Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

31.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oculis Holding Ag

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Oculis Holding (OCS) Earnings & Revenues

Historic Earnings Reports

OCS Stock 12 Month Forecast

Average Price Target

$37.60

▲(237.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","32":"$32","43":"$43","54":"$54"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$53.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,21,32,43,54],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,14.516923076923078,17.723846153846154,20.93076923076923,24.137692307692305,27.34461538461538,30.551538461538463,33.75846153846154,36.965384615384615,40.17230769230769,43.379230769230766,46.58615384615384,49.793076923076924,{"y":53,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,13.332307692307692,15.354615384615386,17.376923076923077,19.39923076923077,21.42153846153846,23.443846153846152,25.466153846153844,27.488461538461536,29.510769230769228,31.53307692307692,33.55538461538461,35.57769230769231,{"y":37.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.31,12.20923076923077,13.108461538461539,14.007692307692308,14.906923076923077,15.806153846153848,16.705384615384617,17.604615384615386,18.503846153846155,19.403076923076924,20.302307692307693,21.201538461538462,22.10076923076923,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.97,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.03,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.53,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.31,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >